AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Genmab A/S (GMAB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.77

0.47 (2.21%)

At close: Feb 18, 2025, 3:59 PM

21.95

0.80%

After-hours: Feb 18, 2025, 05:11 PM EST

undefined% (undefined)

Bid	21.5
Market Cap	13.84B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	1.69
PE Ratio (ttm)	12.88
Forward PE	n/a
Analyst	Buy

Ask	21.95
Volume	1,675,875
Avg. Volume (20D)	1,353,935
Open	21.30
Previous Close	21.30
Day's Range	21.30 - 21.79
52-Week Range	18.64 - 31.88
Beta	undefined

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2009

Employees 2,682

Stock Exchange NASDAQ

Ticker Symbol GMAB

Website https://www.genmab.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $47.5, which is an increase of 118.14% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

5 days ago

+6.25%

Genmab shares are trading higher after the company... Unlock content with Pro Subscription

4 weeks ago

-3.81%

Genmab shares are trading lower. The company reported FY24 net sales for Darzalex.

News

1 day ago · seekingalpha.com

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse...

4 days ago · seekingalpha.com

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call February 12, 2025 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Tahamt...

1 month ago · zacks.com

GMAB vs. QGEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more...

1 month ago · zacks.com

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Are Investors Undervaluing Genmab (GMAB) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 months ago · businesswire.com

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody adm...

2 months ago · businesswire.com

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rat...

2 months ago · seekingalpha.com

Genmab Is Too Attractive To Ignore

Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily...

2 months ago · businesswire.com

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free surviv...

2 months ago · proactiveinvestors.co.uk

Scancell strikes deal worth up to $630m with Genmab

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish ...